INTERIM REPORT FOR ENZYMATICA AB, JULY 1, 2012 TO SEPTEMBER 30, 2012
Q3 REPORT FOR ENZYMATICA IN BRIEF:
· Net sales totaled SEK 357,520 (34,321) · The result after tax amounted to a loss of SEK 776,007 (loss: 1,194,685) · The loss per share was SEK 0.04 · The equity/assets ratio was 86% (82%) · The preferential rights issue provided Enzymatica with proceeds of SEK 8.2 M before issue expenses · The ColdZyme ® Mouth Spray was registered with the Swedish Medical Products Agency · Enzymatica appointed a Scientific Advisory Board
EVENTS AFTER THE CLOSE OF THE PERIOD:
·